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ABSTRACT
Morphine is metabolized in humans to morphine-3-glucuronide
(M3G) and the pharmacologically active morphine-6-glucuronide
(M6G). The hepatobiliary disposition of both metabolites relies
upon multidrug resistance-associated proteins Mrp3 and Mrp2,
located on the sinusoidal and canalicular membrane, respectively.
Nonalcoholic steatohepatitis (NASH), the severe stage of non-
alcoholic fatty liver disease, alters xenobiotic metabolizing
enzyme and transporter function. The purpose of this study was
to determine whether NASH contributes to the large interindivid-
ual variability and postoperative adverse events associated with
morphine therapy. Male Sprague-Dawley rats were fed a control
diet or a methionine- and choline-deficient diet to induce NASH.
Radiolabeled morphine (2.5 mg/kg, 30 mCi/kg) was administered
intravenously, and plasma and bile (0–150 or 0–240minutes), liver
and kidney, and cumulative urine were analyzed for morphine and
M3G. The antinociceptive response to M6G (5 mg/kg) was as-
sessed (0–12 hours) after direct intraperitoneal administration
since rats do not produce M6G. NASH caused a net decrease in
morphine concentrations in the bile and plasma and a net increase in
theM3G/morphine plasma area under the concentration-time curve
ratio, consistent with upregulation of UDP-glucuronosyltransferase
Ugt2b1. Despite increased systemic exposure to M3G, NASH
resulted in decreased biliary excretion and hepatic accumula-
tion of M3G. This shift toward systemic retention is consistent
with the mislocalization of canalicular Mrp2 and increased ex-
pression of sinusoidalMrp3 inNASHandmay correlate to increased
antinociception by M6G. Increased metabolism and altered trans-
porter regulation in NASH provide a mechanistic basis for inter-
individual variability in morphine disposition that may lead to
opioid-related toxicity.
Introduction
Variable drug responses (VDRs) are a widespread clinical
occurrence; for instance, adverse drug events occur in 1 in
20 hospital patients in the United States (Stausberg, 2014).
Large interindividual variability in the expression and function
of hepatic xenobiotic metabolizing enzymes and transport pro-
teins contributes to dose-limiting toxicities of certain thera-
peutics (Yang et al., 2013). Understanding the mechanisms
underlying this variability can help identify susceptible patient
populations. Opioid-related adverse events occur in approx-
imately 15% of postoperative patients in the clinical setting
(Kessler et al., 2013) and represent a subset of VDRs that
may be attenuated by considering altered function of opioid
metabolizing enzymes and transporters (Fujita et al.,
2010).
Nonalcoholic steatohepatitis (NASH) is the severe stage of
progressive nonalcoholic fatty liver disease (NAFLD). NAFLD
is characterized by fatty acid accumulation in the liver at 5% by
weight and progresses to NASH with hepatocellular injury, in-
flammation, and fibrosis (Marra et al., 2008). Epidemiologic
studies estimate the prevalence of NAFLD and NASH to be
30–40% and 5–17%, respectively, in the United States
(McCullough, 2004). Beyond the histologic hallmarks of
NASH, alterations in the expression and function of xenobiotic
metabolizing enzymes and transporters have been described.
Several cytochromesP450,UDP-glucuronosyltransferases (UGTs),
sulfotransferases, and glutathione-S-transferases have shown
altered mRNA and protein expression and, in some cases,
function (Fisher et al., 2009; Hardwick et al., 2010, 2013). A
comprehensive transcriptomic analysis of human NASH re-
vealed a global downregulation of uptake transporters, and an
investigation into ATP-binding cassette transport proteins
revealed increased expression of many efflux transporters
(Hardwick et al., 2011; Lake et al., 2011). However, despite
increased expression, multidrug resistance-associated pro-
tein MRP2 was improperly localized in human NASH liver
samples, potentially reducing function.
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MRP2 is a biliary efflux transporter that shuttles xenobiotic
conjugates into the bile (Keppler et al., 1997), which may be
disrupted during the development of cholestasis (Mottino
et al., 2002). MRP2 shares substrate specificity with MRP3,
a sinusoidal efflux transporter with increased expression in
NASH (Hardwick et al., 2011). A recent study showed that
the MRP2/MRP3 substrate ezetimibe exhibits decreased
biliary excretion and increased plasma retention in a rodent
model of NASH (Hardwick et al., 2012). Although ezetimibe is
relatively safe with minimal dose-limiting toxicity, this ob-
servation indicates that NASH patients taking other drugs
that use the MRP2/MRP3 system for hepatobiliary disposition
may be at risk for increased and prolonged systemic drug
exposure.
Morphine, a potent opioid receptor agonist, is used extensively
in the clinic to treat intense and prolonged pain. Morphine is
metabolized in humans by UGT2B7 to the abundant metabolites
morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G) (Chen et al., 1991; Coffman et al., 1997). Despite sim-
ilar structures, these metabolites have differing pharmaco-
logic properties. M3G, the more abundant metabolite, has
been shown to be antagonistic against the pharmacologic
activities of morphine (Smith et al., 1990; Handal et al.,
2007). M6G, although less abundant, is pharmacologically
active and is responsible for the majority of the therapeutic
benefit of morphine (Osborne et al., 1992). Studying M6G
activity in rodents is complicated, because although mor-
phine is metabolized to both glucuronides by human UGT2B7,
rodent Ugt2b1 metabolizes morphine exclusively to M3G
(Kuo et al., 1991; Salem and Hope, 1997; Hasegawa et al.,
2009). Nevertheless, hepatic-derived M3G and exogenously
administered M6G are substrates for human and rodent
MRP2/Mrp2 and MRP3/Mrp3, which are responsible for
their hepatobiliary disposition (Zelcer et al., 2005; van de
Wetering et al., 2007; Hasegawa et al., 2010). Biliary ex-
cretion, representing up to 20% of morphine glucuronide
clearance (Garrett and Jackson, 1979; Ouellet and Pollack,
1995), is mediated by Mrp2. Previous studies examined
the pharmacokinetics of M3G in rats with streptozotocin-
induced diabetes and bile duct ligation–induced cholestasis
(Hasegawa et al., 2009, 2010). Both disease states altered
the expression of Ugt2b1, Mrp3, and Mrp2 and negatively
affected the biliary excretion of M3G. Furthermore, Mrp32/2
mice show decreased M6G-induced antinociception com-
pared with wild-type mice, due to increased biliary excretion
(Zelcer et al., 2005). Variations that alter the M6G/morphine
ratio could have substantial pharmacodynamic consequences
(Murthy et al., 2002).
Given the functional alterations of Mrp2 and Mrp3 ob-
served previously in rodent models of NASH, it was hy-
pothesized that NASH would result in decreased biliary
excretion of hepatic-generated M3G and exogenously ad-
ministered M6G, leading to a perturbation in systemic M6G
exposure and subsequent increase in the analgesic effect of
M6G. This study aimed to examine the pharmacokinetics of
morphine and M3G in a rodent model of NASH, provide
a mechanistic basis for these alterations, and determine the
corresponding analgesic effect of altered M6G disposition.
Comparison of the morphine/M3G pharmacokinetic and M6G
effect profiles observed in NASH models may provide a mech-
anistic understanding and prediction of response in patients
with NASH.
Materials and Methods
Morphine sulfate salt pentahydrate and urethane were purchased
from Sigma-Aldrich (St. Louis, MO). Morphine-6-b-D-glucuronide
was purchased from Lipomed, Inc. (Cambridge, MA). Morphine
[N-methyl-3H] was purchased from American Radiolabeled Chemicals
(St. Louis, MO). TLC Silica Gel 60 F254 plates were purchased from
EMD Millipore (Billerica, MA). UltimaGold, Solvable, and InstaGel
Plus scintillation cocktails were purchased fromPerkinElmer (Waltham,
MA). n-Butanol and glacial acetic acid were purchased from Alfa Aesar
(Ward Hill, MA) and Amresco (Solon, OH), respectively.
Animals. Male Sprague-Dawley rats weighing 200–250 g were
obtained from Harlan (Indianapolis, IN). Animals were acclimated in
12-hour light/dark cycles in a University of Arizona Association for
Assessment and Accreditation of Laboratory Animal Care–certified
animal facility for at least 1 week before experiments and were
allowed water and standard chow ad libitum. Handling, care, mainte-
nance, and testing of the animals were in accordance with the policies
and recommendations of the International Association for the Study of
Pain and the National Institutes of Health guidelines for the handling
and use of laboratory animals. The experimental protocol was approved
by the Institutional Animal Care andUseCommittee at theUniversity of
Arizona. Rats were fed either a control diet with methionine and
choline or a methionine- and choline-deficient (MCD) diet (Dyets Inc.,
Bethlehem, PA) ad libitum for 8 weeks prior to the pharmacokinetic
studies. At 7.5 weeks on the diet, rats underwent radiant heat studies;
at 8 weeks on the diet, rats underwent morphine disposition studies.
M6G Antinociception. The protocol for the measurement of
thermal nociception was derived from a previously published method
(Hargreaves et al., 1988). Rats (n 5 6 to 7 per experimental group)
were acclimated for 30 minutes in individual plexiglass stalls on
tempered glass. Radiant heat (infrared5 40) was directed toward the
plantar surface of their hind paw until paw withdrawal interrupted
the heat source and the timer. Withdrawal latencies were measured
using an automated motion detector with a maximum cutoff of 32.6
seconds to prevent tissue damage. Pawwithdrawal latencieswere recorded
to the nearest 0.1 seconds both before M6G or vehicle administration
and at t 5 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390,
420, 450, 480, 540, 600, 660, and 720 minutes after intraperitoneal
injection of either saline (vehicle) or M6G (5 mg/kg).
Morphine and M3G Disposition. Rats were anesthetized with
an intraperitoneal bolus dose of urethane (1 g/kg). The disposition of
morphine and M3G in blood and bile was assessed via cannulation
surgeries of the jugular vein for drug administration, carotid artery
for blood collection, and bile duct for bile collection. After a 3-minute
intravenous infusion of 2.5mg/kgmorphine per 30 mCi/kg [3H]morphine,
blood, bile, and urine were collected for 150 minutes, followed im-
mediately with terminal liver and kidney collection. Plasma morphine
and M3G concentrations over a longer time period were assessed by
cannulation of the femoral vein for drug administration and the femoral
artery for blood collection. After a 3-minute intravenous infusion of
2.5 mg/kg morphine per 30 mCi/kg [3H]morphine, blood was collected for
240 minutes. Blood samples were centrifuged for 10 minutes at 10,000g
to separate plasma from blood cells. Liver slices were prepared for
histologic analysis and placed in 10% neutral-buffered formalin for at
least 24 hours followed by 70% ethanol until paraffin embedding by the
University of Arizona Histology Service Laboratory. The remaining
tissue was snap-frozen in liquid nitrogen. All samples were stored at
280°C for later analysis.
Thin Layer Chromatography and Scintillation Counting.
Total radioactivity was determined by diluting 15 ml of plasma, bile,
or urine with 5 ml UltimaGold scintillation cocktail. Liver or kidney
(50 mg) was disintegrated in 500 ml Solvable for 4 hours at 60°C and
mixed with 5 ml UltimaGold. The percent contribution of morphine
and M3G was determined by separating the compounds in 15 ml of
plasma, bile, or urine and in 40 ml of liver and kidney homogenate
(50 mg tissue in 300 ml saline) supernatant on silica-coated glass
plates with a mobile phase of 35:3:10 n-butanol/acetic acid/water
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(Yeh, 1973). Morphine and morphine glucuronide standards were run
on every plate and corresponding retention factors were scraped and
counted for radioactivity (Rf morphine 5 0.2, Rf M3G 5 0.02).
Scrapings of silica gel were added to 2 ml water and incubated for
3 hours at 40°C prior to dissolution in 5 ml InstaGel Plus. All samples
were counted as disintegrations perminute of tritium using a Beckman
LS6500 scintillation counter (Beckman Coulter, Inc., Brea, CA) and
converted to concentrations using the specific activity of the compound
and the molar mass and percent contribution of either morphine or
M3G. The pharmacokinetics of morphine and M3G were determined
via noncompartmental analysis using Phoenix WinNonlin (version 6.3;
Certara, St. Louis, MO).
Protein Preparations. Whole-cell lysate preparations of rat liver
tissue were prepared from 300 mg tissue homogenized in NP40 buffer
[20 mM Tris-HCl, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, and
2 mM EDTA with 1 Protease Inhibitor Cocktail Tablet (Roche,
Indianapolis, IN) per 25 ml] at 4°C. Homogenized tissue was agitated
at 4°C for 2 hours and centrifuged at 10,000g for 30 minutes, and the
supernatant was transferred to a clean collection tube. Protein con-
centrations were determined using the Pierce BCA Protein Quanti-
tation Assay (Thermo Fisher Scientific, Waltham, MA) per the
manufacturer’s recommendations.
Immunoblot Protein Analysis. Whole-cell liver lysate (50 mg)
was separated by SDS-PAGE on 7.5% polyacrylamide gels, and the
Fig. 1. Liver histopathology of MCD diet–induced NASH. Representative
hematoxylin and eosin–stained liver sections of control rats and rats fed
an MCD diet for 8 weeks. MCD-fed rats demonstrated the characteristic
features of NASH, including steatosis and inflammation. Rats fed control
diet had healthy livers with no evidence of steatosis. Original magnifica-
tion, 40.
Fig. 2. Effect of MCD diet–induced NASH on systemic exposures of
morphine and M3G. Plasma concentration of morphine (A and C) and
M3G (B and D) over 150 minutes (A and B) and 240 minutes (C and D)
after intravenous administration of 2.5 mg/kg morphine to control (closed
circles) and NASH (open squares) rats. Plasma AUC graphs represent
means 6 S.D. (n = 4–6 for each group). *P # 0.05; ***P # 0.001 (t test).
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proteins were transferred to nitrocellulose (Mrp3) or polyvinylidene
difluoride (Ugt2b) membranes, followed by blocking of nonspecific
sites with 5% nonfat dry milk in Tris-buffered saline/Tween 20. The
primary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX)
sc-5775 (Mrp3) or sc23479 (Ugt2b) were diluted to 1:500 in blocking
solution. Relative protein expression was determined using image
processing and analysis with ImageJ software (National Institutes of
Health, Bethesda, MD) and normalized to the housekeeping protein
Erk (Sc-93 and sc-154; Santa Cruz Biotechnology, Inc.).
RNA Purification. Total RNA was extracted from rat liver using
RNAzol B reagent (Tel-Test, Inc., Friendswood, TX) per the manufac-
turer’s protocol. RNA concentrations were determined using a Nano-
Drop 2000 UV-visible spectrophotometer (Thermo Fisher Scientific).
RNA integrity was confirmed by ethidium bromide staining after
agarose gel electrophoresis.
Branched-Chain DNA Analysis. RNA (10 mg) was allowed to
hybridize to specific oligonucleotide probes for Ugt2b1 diluted in lysis
buffer overnight at 53°C in a 96-well plate format with signal
amplification steps occurring the following day. Substrate solution,
lysis buffer, capture hybridization buffer, amplifier, and label probe
used for the assay were obtained from the Quantigene Discovery Kit
(Affymetrix, Santa Clara, CA). Luminescence was measured with
a Quantiplex 320 bDNA Luminometer interfaced with Quantiplex
Data Management Software (version 5.02; Bayer, Walpole, MA). A
background reading from a well consisting of all reagents except RNA
was subtracted from sample readings to determine expression above
background level.
Immunohistochemistry. Immunohistochemical staining for
Mrp2 was performed on formalin-fixed, paraffin-embedded samples.
Liver sections were deparaffinized in xylene and rehydrated in
ethanol, followed by antigen retrieval with Tris-EDTA buffer, pH 9.0.
Endogenous peroxidase activity was blocked with 0.3% (v/v) hydrogen
peroxide inmethanol for 20minutes. Mrp2 staining was performed by
incubation with the M2III-5 clone (1:80) (Kamiya Biomedical, Seattle,
WA) for 2 days at 20°C followed by the MACH3 staining kit (Biocare
Medical, Concord, CA) per the manufacturer’s protocol.
Statistical Analysis. Statistical comparisons between control and
MCD groups weremade using an unpaired two-way t test in GraphPad
Prism software (version 5.0; GraphPad Software Inc., La Jolla,
CA). Significance levels of P # 0.05, P # 0.01, and P # 0.001 were
determined.
Results
Effect of MCD Diet–Induced NASH on Morphine and
M3G Disposition. Histologic evaluation of hematoxylin and
eosin–stained liver sections was performed under light
microscopy at 40 magnification (Fig. 1). Rats that received
the 8-week MCD diet exhibited NASH hallmarks, including
steatosis, inflammation, and fibrosis, consistent with previous
reports wherein this model was scored by a trained pathologist
using a validated NASH scoring system (Kleiner et al., 2005;
Canet et al., 2014) and identified as histologically similar to
human NASH (George et al., 2003). The effect of NASH on
morphine and M3G disposition after intravenous administra-
tion of morphine was examined over 150 minutes. Relative to
control rats,morphine systemic exposure, assessed by the plasma
area under the concentration-time curve (AUC) decreased in
NASH rats to 74% of control (Fig. 2A), and M3G exposure
increased to 150% of control (Fig. 2B). Similar trends were
Fig. 3. Biliary excretion of morphine and M3G. Cumu-
lative biliary excretion of morphine (A) and M3G (B) in
the bile was measured over 150 minutes after in-
travenous administration of 2.5 mg/kg morphine to
control (closed circles) and NASH (open squares) rats.
Bile AUC graphs represent means6 S.D. (n = 5 for each
group). **P # 0.01 (t test).
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observed with the longer time course (0–240 minutes):
morphine AUC decreased in NASH rats to 45% of control
(Fig. 2C) and M3G increased to roughly 150% of control (Fig.
2D). The terminal phases of both the morphine and M3G
concentration-time profiles from both time courses were not
sufficiently captured to recover accurate estimates of terminal
elimination half-life (morphine, M3G), systemic clearance
(morphine), and steady-state volume of distribution (mor-
phine). The areas under the biliary excretion-time curves for
morphine and M3G decreased to 45 and 48% of control,
respectively, and biliary clearance of morphine decreased from
70 6 14 to 25 6 9.0 ml/min (Fig. 3).
Hepatic and renal morphine concentrations (Fig. 4, A and
B, left panels) and the amount of morphine excreted un-
changed into the urine (Fig. 4C, left panel) were not different
between groups. Hepatic M3G concentration decreased to
37% of control (Fig. 4A, right panel). Urinary M3G excretion
reflected renal M3G concentrations, as evidenced by an
apparent increase in NASH rats that did not reach signifi-
cance (Fig. 4, B and C, right panels).
Effect of MCD Diet–Induced NASH on Mrp3 and
Mrp2. Relative protein levels of Mrp3 were analyzed by
immunoblotting with a representative image and densito-
metric analysis shown in Fig. 5A. Mrp3 in NASH rats
increased to almost 160% of control. Representative images
of immunohistochemical staining of Mrp2 in control and
NASH formalin-fixed paraffin-embedded liver samples are
shown in Fig. 6 at 100 magnification. Staining of Mrp2 in
control liver indicated proper localization to the canalicular
membrane, whereas Mrp2 staining in the NASH liver ap-
peared to pocket inward, suggesting that this efflux trans-
porter is improperly localized in the disease model.
Morphine Metabolism in MCD Diet–Induced NASH.
Relative protein expression of the Ugt2b subfamily, which
includes Ugt2b1, the isoform responsible for converting mor-
phine to M3G, was assessed by immunoblot analysis with
a representative image and densitometric analysis shown in
Fig. 5A. In general, overall Ugt2b protein levels appeared
unaltered in NASH rats. Branched-chain DNA analysis
revealed an upregulation of Ugt2b1 mRNA in NASH rats to
800% of control (Fig. 5B). The metabolite/parent plasma
AUC ratios for both time courses were higher in NASH rats
to $ 300% of control (data not shown).
M6G-Induced Antinociception in MCD Diet–Induced
NASH. Control andNASH ratswere administeredM6G (n5 7)
or vehicle (saline, n 5 6) intraperitoneally and monitored for
12 hours for antinociceptive response to radiant heat to the hind
paw. NASH rats administered M6G showed a significantly
delayed response to stimuli (Fig. 7A). Vehicle-treated control
rats did not demonstrate an increase in withdrawal latency
times from baseline; however, vehicle-treated NASH rats
maintained a significantly increased delay in stimuli response
compared with control rats (Fig. 7B). NASH rats showed an
apparent increase in baseline withdrawal latency relative to
control rats that did not reach significance (P 5 0.0518, t test).
Discussion
Examination of postoperative pain management programs
indicates that nearly 100% of patients are treated with opi-
oids; of these patients, 15% experience opioid-related adverse
events (Kessler et al., 2013). More concerning is that although
opioids are becoming less common, they continue to be pre-
scribed for outpatient management of chronic pain, a setting
that is less likely to be extensively monitored and represents
a higher risk for mortality (Labianca et al., 2012). Obesity,
a condition closely linked with NAFLD (McCullough, 2011), is
one identified risk factor for these toxicities. NASH, the later
Fig. 4. Hepatic, renal, and urinary levels of morphine and M3G. Levels of
morphine (left) and M3G (right) in terminal liver (A) and kidney (B) and
cumulative urine (C) were determined after intravenous administration of
2.5 mg/kg morphine to control and NASH rats. Graphs represent means6
S.D. **P # 0.01 (t test).
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stage of NAFLD, is characterized not only by histopathologic
consequences but also by alterations in the expression and
function of vital phase I and II drug metabolizing enzymes
and transport proteins (Fisher et al., 2009; Hardwick et al.,
2010, 2013; Lake et al., 2011). Previous studies have
confirmed corresponding shifts in the disposition of certain
xenobiotics in rodent models of NASH (Canet et al., 2012;
Hardwick et al., 2012; Clarke et al., 2014), which may also
alter the toxicodynamic profile (Hardwick et al., 2014) and
contribute to VDRs derived from a number of therapeutics.
Morphine, one of the most commonly prescribed opioids, is
metabolized extensively in humans by UGT2B7 to the major
metabolite M3G (Smith et al., 1990; Coffman et al., 1997) and
the minor, pharmacologically active metabolite M6G (Osborne
et al., 1992; Coffman et al., 1997;Murthy et al., 2002). Although
M3G lacks analgesic activity, it has been shown to target other
pathways, such as the Toll-like receptor 4 pathway, to elicit
neuroexcitatory effects (Due et al., 2012). Despite differing
pharmacologic properties, the pharmacokinetic properties of
these metabolites are comparable (Handal et al., 2002). Mor-
phine glucuronidation in rodents differs from that by human
UGT2B7, in that it is mediated by Ugt2b1, which predomi-
nantly produces M3G, whereas M6G formation is negligible
(Kuo et al., 1991).Morphine andM3Gdispositionwere compared
between control and NASH rats assuming similar pharmacoki-
netic profiles between hepatically derived M3G and exogenously
administered M6G.
This study aimed to examine NASH as a contributing factor
to the interindividual variability in morphine and correspond-
ing glucuronide metabolite disposition using an established
rat model of NASH. The MCD diet has an accelerated rate of
NASH development compared with the chronic human con-
dition and does not recapitulate the common human comorbid-
ities of obesity, insulin resistance, and diabetes. Nevertheless,
for the purposes of drug disposition studies, the MCD diet
closely resembles human NASH with respect to hepatic trans-
porter regulation (Rinella and Green, 2004; Canet et al., 2014).
The MCD diet–induced NASH in this study exhibited the
expected changes in liver histology and transporter regulation.
Compared with control rats, M3G in NASH rats exhibited
increased plasma retention coupled with significantly re-
duced biliary excretion. M3G hepatobiliary disposition is
dependent on canalicular MRP2/Mrp2 for biliary efflux and
sinusoidal MRP3/Mrp3 for extrusion into the blood (Zelcer
et al., 2005; van de Wetering et al., 2007). It was previously
Fig. 5. MCD diet–induced NASH alterations in Mrp3 and Ugt2b. (A)
Relative protein levels of Mrp3 (left) and Ugt2b (right) expression in
control and NASH rats were assessed by immunoblot analysis and
normalized to total Erk1 and Erk2. (B) Relative mRNA expression of rat
Ugt2b1 was measured by branched-chain DNA analysis. Graphs repre-
sent means 6 S.D. (n = 10). *P # 0.05; ***P # 0.001 (t test).
Fig. 6. MCD diet–induced NASH altered localization of Mrp2. Immuno-
histochemical staining of Mrp2 in formalin-fixed paraffin-embedded control
and MCD rat liver samples is shown. Original magnification, 100.
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established that MRP3/Mrp3 protein expression is increased
in human NASH (Hardwick et al., 2011) and in the rat MCD
model (Hardwick et al., 2012; Canet et al., 2014), an ob-
servation that was confirmed in this study. In addition,
MRP2/Mrp2 has garnered much interest due to the observa-
tion that in NASH, this transporter appears to bemislocalized
(Hardwick et al., 2011, 2012), a phenomenon that also occurs
in cholestasis and acute oxidative stress (Mottino et al., 2002;
Sekine et al., 2006), and was confirmed in this study via
immunohistochemistry. Several previous disposition studies
have demonstrated a shift from biliary excretion of known
MRP2/Mrp2 substrates and metabolites (Lickteig et al., 2007;
Hardwick et al., 2012, 2014) to an increased systemic ex-
posure, providing credence to the notion that MRP2/Mrp2 has
diminished function in NASH. Accordingly, this study reports
the altered disposition of another glucuronide, a common
shared substrate for the MRP2/MRP3 system.
The decreased biliary excretion of M3G was accompanied by
decreased hepatic M3G levels. Decreased morphine uptake into
the liver could explain this observation but is unlikely because
the liver is the primary site of glucuronidation, and morphine
uptake into the liver appeared unimpaired because M3G for-
mation was unimpaired. A more likely explanation is that di-
minishedMrp2 function coupled with increasedMrp3 expression
coordinately shuttled M3G back into systemic circulation. This
reasoning is consistent with previous investigations involving
bile duct ligation–induced cholestasis and streptozotocin-induced
diabetes, which identified an increased systemic retention of
M3G that may be attributed to perturbed expression of hepatic
Mrp2 and Mrp3 (Hasegawa et al., 2009, 2010). As further
evidence for the role of Mrp2 and Mrp3 in M3G disposition, we
observed significantly less M3G in the bile of NASH rats, despite
the net increase inM3G levels. This net increase inM3G levels is
likely due to the increasedmRNA expression of Ugt2b1 inNASH
rats. A previous study indicated no significant change inUGT2B7
mRNA expression in human NAFLD (Hardwick et al., 2013);
therefore, we do not expect any changes in glucuronide formation
in human NASH. These data clearly indicate a transporter-
mediated decrease in biliary excretion and increased plasma
retention of the glucuronide morphine metabolites.
Given the decreased biliary excretion of M3G, increased
urinary excretion or kidney retention was expected. Renal
and urinary amounts of morphine in NASH were unchanged,
as expected; although M3G exhibited an apparent increase in
renal and urinary amounts, these changes did not reach sig-
nificance. The high variability in urinary output likely con-
tributed to this observation. In addition, human NASH has
been shown to affect glomerular filtration rates (Targher
et al., 2010), which may also occur in the rat NASH model.
The pharmacokinetic aspects of this study suggest a func-
tional consequence of altered Mrp2 localization coupled with
increased Mrp3 expression, which is a shift in disposition of
Fig. 7. Analgesic effects of exogenous M6G in MCD
diet–induced NASH. Control (closed circles) or NASH
(open squares) rats were administered either 5 mg/kg
M6G (A) or volume-matched saline (B) andweremonitored
for withdrawal latency every 30 minutes for 720 minutes.
The AUC data represent means 6 S.D. (n = 6 to 7 per
group). *P # 0.05; **P # 0.01 (t test).
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the shared substrate, M3G. M3G is the major metabolite, but
does not contribute to analgesic activity; by contrast, M6G
is responsible for the majority of morphine activity. Given
similar pharmacokinetic profiles between the two metabolites
(Handal et al., 2002), increased M6G exposure would have
toxicodynamic consequences. Because rats do not generate
M6G, exogenous M6G was administered to control and NASH
rats to determine whether an increased systemic exposure
correlated with an increased pharmacologic effect, assessed
via antinociceptive response. This test has been used pre-
viously in an Mrp32/2 mouse model, and M6G-induced anti-
nociception positively correlated with M3G plasma exposure
(Zelcer et al., 2005). As expected, NASH rats exhibited
a higher response to M6G in terms of area under the with-
drawal latency curve, a measure of the time lapse between
thermal stimulus and paw withdrawal. A dietary effect was
also tested by administering saline instead of M6G to control
and NASH rats and monitoring over the same 12-hour period.
Overall latency times were lower for both groups; that is,
saline had less of an effect than M6G, as expected. Neverthe-
less, NASH rats administered saline, although not significantly
different from control at baseline, maintained a statistically
significant increase in withdrawal latency times compared
with control rats, independent of treatment. Given the na-
ture of the model (an MCD system), the observation that
choline deficiency alone would affect the responsiveness of
these rats was not unexpected. Circulating acetylcholine
levels are readily affected by dietary choline intake (Nakamura
et al., 2001). Perturbations in acetylcholine levels affect mem-
ory and spatial learning performance (Fadda et al., 2000); the
control rats in both treatment groups became more responsive
over time, whereas the NASH rats took a longer time to
associate the sensation relief with paw withdrawal. Prolonged
choline deficiency has also been shown to decrease locomotor
activity, which could contribute to higher latencies (Beninger
et al., 1984). Even with the diet-induced effect on withdrawal
latency measurements, transporter-mediated increases in the
effect of M6G in NASH would lead to a larger magnitude of
difference between average control and NASH withdrawal
latencies. However, the NASH rats given M6G reached a
ceiling effect due to the required cutoff of 32.6 seconds of
radiant heat exposure. Collectively, because of the limita-
tions of the NASH model and the assay, a pharmacodynamic
consequence of altered morphine glucuronide disposition
could not be determined.
In summary, this study demonstrated significantly increased
morphine metabolism to M3G in a rodent model of NASH as
a result of Ugt2b1 induction. Despite the increased systemic
M3G exposure, biliary excretion decreased significantly due to
the mislocalization and consequent decrease in function of the
canalicular efflux transporter Mrp2. The induced expression of
sinusoidal Mrp3 led to increased systemic M3G exposure that
may also increase exposure to both M3G and active M6G in
humans with NASH. These data suggest that alterations in
transporter function provide a mechanistic basis for opioid-
related VDRs in patients with NASH.
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